Is anti-TNF therapy safer than previously thought?

JAMA

Volumn 306, Issue 21, 2011, Pages 2380-2381

  Dixon, Will ^a,b   Felson, David T ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EDITORIAL; HUMAN; INFECTION; INFECTION RATE; INFECTION RISK; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS;

EID: 83055163731     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1705     Document Type: Editorial

References (16)

1. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases [published online November 6, 2011]. JAMA. 2011;306(21):2331-2339.
2. Maini R, St Clair EW, Breedveld F, et al. ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354(9194):1932-1939.
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti- TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285. (Pubitemid 43736578)
4. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis. 2009;68(8):1240-1246.
5. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patientswith rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189-194. (Pubitemid 351183307)
6. Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40(1):2-14, e1.
7. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-3412. (Pubitemid 41612206)
8. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20(2):138-144. (Pubitemid 351339884)
9. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011; 70(11):1914-1920.
10. Dixon WG, Carmona L, Finckh A, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010;69(9):1596-1602.
11. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patientswith rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896-2904. (Pubitemid 47502735)
12. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125-1133. (Pubitemid 46608637)
13. Dixon WG,Watson K, Lunt M,et al. Rates of serious infection, including site-specific andbacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(8):2368-2376. (Pubitemid 44204996)
14. Nilsson AC, Christensen AF, Junker P, Lindegaard HM.Tumour necrosis factor-αinhibitors are glucocorticoid-sparing in rheumatoid arthritis. Dan Med Bull. 2011; 58(4):A4257.
15. Hetland ML,Christensen IJ, Tarp U,etal. Direct comparison of treatment responses, remission rates, and drug adherence in patientswith rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. Arthritis Rheum. 2010;62(1):22-32.
16. Busquets N, Tomero E, Descalzo MA, et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford). 2011;50(11):1999-2004.